Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497561 | PMC |
| http://dx.doi.org/10.1038/s41408-023-00918-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
scTrends: A living review of commercial single-cell and spatial 'omic technologies.
Cell Genom
December 2024
Relation Therapeutics, London, UK. Electronic address:
Understanding the rapidly evolving landscape of single-cell and spatial omic technologies is crucial for advancing biomedical research and drug development. We provide a living review of both mature and emerging commercial platforms, highlighting key methodologies and trends shaping the field. This review spans from foundational single-cell technologies such as microfluidics and plate-based methods to newer approaches like combinatorial indexing; on the spatial side, we consider next-generation sequencing and imaging-based spatial transcriptomics.
View Article and Find Full Text PDFUnderstanding and overcoming resistance to tyrosine kinase inhibitors (TKIs) in Chronic myeloid leukemia (CML).
Expert Rev Hematol
December 2024
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
Introduction: Chronic myeloid leukemia (CML) represents one of the first neoplasms whose molecular pathogenesis was successfully unraveled, with tyrosine kinase inhibitors (TKIs) representing one of the first-targeted therapies. TKIs have revolutionized long-term outcomes of CML patients and their life expectancy. Nonetheless, a minority of patients will develop TKI resistance due to a complex and multifactorial process that ultimately leads to the emergence of an unresponsive cancer clone.
View Article and Find Full Text PDFChemotherapeutic potential of radotinib against blood and solid tumors: A beacon of hope in drug repurposing.
Bioorg Chem
December 2024
Molecular Toxicology Laboratory, Department of Biotechnology, Bharathiar University, Coimbatore 641046, India. Electronic address:
Tyrosine kinase inhibitors (TKIs) represent a pivotal class of targeted therapies in oncology, with multiple generations developed to address diverse molecular targets. Imatinib is the first TKI developed to target the BCR-ABL1 chimeric protein, which is the key driver oncogene implicated in Philadelphia chromosome-positive chronic myeloid leukemia (CML). Several second-generation tyrosine kinase inhibitors (2GTKIs), such as nilotinib, dasatinib, bosutinib, and radotinib (RTB), followed the groundbreaking introduction of imatinib.
View Article and Find Full Text PDFSingle cell variant to enhancer to gene map for coronary artery disease.
medRxiv
November 2024
Center for Cardiovascular Research, Division of Cardiology, Department of Medicine, Washington University School of Medicine, Saint Louis, MO, 63110, USA.
Although genome wide association studies (GWAS) in large populations have identified hundreds of variants associated with common diseases such as coronary artery disease (CAD), most disease-associated variants lie within non-coding regions of the genome, rendering it difficult to determine the downstream causal gene and cell type. Here, we performed paired single nucleus gene expression and chromatin accessibility profiling from 44 human coronary arteries. To link disease variants to molecular traits, we developed a meta-map of 88 samples and discovered 11,182 single-cell chromatin accessibility quantitative trait loci (caQTLs).
View Article and Find Full Text PDFImmune checkpoints PD1/PDL1, TIM3/GAL9 and key immune mediators landscape reveal differential expression dynamics on imatinib response in chronic myeloid leukemia.
Ann Hematol
November 2024
Laboratorio de Genética Hematológica, Instituto de Medicina Experimental, IMEX-CONICET/ Academia Nacional de Medicina, Pacheco de Melo 3081, Ciudad Autónoma de Buenos Aires, C1425AUM, Argentina.
Article Synopsis
- The immune system in chronic myeloid leukemia (CML) patients is significantly weakened, affecting their ability to respond to tumors, but shows improvement following effective treatment with tyrosine kinase inhibitors like imatinib.
- A study analyzed gene expression of various immune mediators in 171 blood samples from CML patients over their first year on imatinib, comparing it with samples from healthy donors.
- Results indicated that most immune mediators initially declined but largely normalized over time, while also revealing different patterns in optimal versus non-optimal treatment responders.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!